Tscan Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
TScan Therapeutics reports increased net losses in 2025, strategically prioritizes its hematologic malignancies program, and pauses solid tumor trial enrollment to focus on in vivo engineering.
NASDAQ
10-K: TScan Therapeutics Reports Progress in Cancer Immunotherapy Trials, Faces Financial Challenges
Clinical-stage biotechnology company TScan Therapeutics is advancing its T cell receptor (TCR)-engineered T cell therapies for cancer, but continues to incur significant losses and requires additional funding.
NASDAQ
TScan Therapeutics has filed an amendment to its 2023 annual report to include previously omitted information regarding directors, executive compensation, and corporate governance.
NASDAQ
TScan Therapeutics formalizes its employment agreement with CEO Gavin MacBeath and files its annual 10-K report, detailing financial performance and strategic direction.